Singapore Tardive Dyskinesia Market Size & Outlook, 2026-2034
Singapore Tardive Dyskinesia Market Insights
- Reed Intelligence analysis indicates that the Singapore Tardive Dyskinesia Market size, valued at USD 15.17 Million in 2025, is expected to expand to USD 35.77 Million by 2034.
- The Singapore market is forecasted to expand at a CAGR of 10.07% spanning 2026–2034.
- VMAT2 Inhibitors held the leading position among Drug Class segments in 2025, based on market size.
- Supportive Therapies is projected to post the fastest growth rate, sustaining its position as the most attractive Drug Class segment during the forecast horizon.
![Singapore Tardive Dyskinesia Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/singapore-tardive-dyskinesia-market-singapore-drug-class-133135.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Singapore represented 0.48% of the overall global Tardive Dyskinesia Market size.
- United States is projected to lead the global Tardive Dyskinesia Market size by 2034.
- Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2034.
- India is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 412.19 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 15.17 Million |
| Market Size In 2034 | USD 35.77 Million |
| Largest segment | VMAT2 Inhibitors |
| Units | Revenue in USD Million |
| CAGR | 10.07% (2026-2034) |
| Segmnetation Covered | |
| Drug Class |
|
| Distribution Channel |
|
| End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Singapore Tardive Dyskinesia Market Drug Class 2026-2034 (USD Million)
| Drug Class | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VMAT2 Inhibitors | XX.x | XX.x | XX.x | 7.35 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dopamine Modulators | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Novel Neuromodulators | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Supportive Therapies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Tardive Dyskinesia Market Distribution Channel 2026-2034 (USD Million)
| Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | XX.x | XX.x | XX.x | 6.08 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retail Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Tardive Dyskinesia Market End Use 2026-2034 (USD Million)
| End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 6.07 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Homecare Settings | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Rehabilitation Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.